# OnCo record atezolizumab (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: .
@prefix onco: .
@prefix owl: .
@prefix xsd: .
a schema:Drug ;
onco:kind "drug" ;
schema:identifier "atezolizumab" ;
schema:name "Atezolizumab"@en ;
schema:description "A PD-L1 blocker used in lung, liver, and bladder cancer. In 2026 it became the first drug approved based on a blood test showing leftover cancer after bladder surgery."@en ;
schema:url ;
schema:dateModified "2026-09-04"^^xsd:date ;
schema:sameAs ;
owl:sameAs ;
schema:citation , , , , , , , , ;
onco:status "approved" ;
onco:modality "Monoclonal antibody (anti-PD-L1)" ;
schema:alternateName "Tecentriq / Tecentriq Hybreza (SC)" ;
onco:approval "US 2016: Urothelial carcinoma (later withdrawn); NSCLC", "US 2026: Adjuvant muscle-invasive bladder cancer, ctDNA-positive after cystectomy", "EU 2019: Unresectable locally advanced or metastatic TNBC with PD-L1 expression of 1 percent or more (SP142 immune cells), with nab-paclitaxel, no prior chemotherapy for metastatic disease (IMpassion130); the indication remains in the EU product information on 24 September 2026", "UK 2020: Triple-negative unresectable locally advanced or metastatic breast cancer with PD-L1 of 1 percent or more, with nab-paclitaxel, untreated for metastatic disease; NICE TA639 (1 July 2020) recommends within the marketing authorisation with a commercial arrangement", "England (NICE) 2018: Locally advanced or metastatic non-small-cell lung cancer after chemotherapy", "England (NICE) 2019: Metastatic non-squamous non-small-cell lung cancer, with bevacizumab, carboplatin and paclitaxel", "England (NICE) 2020: Untreated extensive-stage small-cell lung cancer, with carboplatin and etoposide", "England (NICE) 2021: Untreated metastatic non-small-cell lung cancer with PD-L1 on at least 50 percent of tumour cells or 10 percent of tumour-infiltrating immune cells and no EGFR or ALK alteration", "England (NICE) 2025: Adjuvant treatment of resected non-small-cell lung cancer after platinum chemotherapy, where PD-L1 is on 50 percent or more of tumour cells and the tumour is not EGFR-mutant or ALK-positive" ;
onco:acceleratedApproval "US 2016-05-18: Locally advanced or metastatic urothelial carcinoma that progressed during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy", "US 2017-04-17: Patients with locally advanced or metastatic urothelial carcinoma (mUC) who are not eligible for cisplatin-containing chemotherapy and whose tumors express PD-L1 as determined by an FDA approved test or who are not eligible for any platinum-containing chemotherapy regardless of PD-L1 status", "US 2019-03-08: In combination with paclitaxel protein-bound for unresectable locally advanced or metastatic triple-negative breast cancer whose tumors express PD-L1 (PD-L1 stained tumor-infiltrating immune cells of any intensity covering = 1% of the tumor area), as determined by an FDA-approved test." ;
onco:related , , ;
onco:cancers , , , , , , , , , , , , , ;
onco:technologies , ;
onco:targets ;
onco:companies , ;
onco:trials , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ;
onco:keyPapers , .